• Diagnosis of Tick-Borne Infectious Diseases in the United States

    Diagnosis of Tick-Borne Infectious Diseases in the United States
    Originally published by our sister publication Infectious Disease Special EditionTaylor D. Ticer, PhD, and Nicole A. Loeven, PhD, D(ABMM)Vector-borne diseases (VBDs) are a serious worldwide public health threat, responsible for more than 17% of all infectious diseases.1 These diseases are caused by a vast array of microorganisms including bacteria, viruses, and parasites, and can be transmitted by an even wider variety of vectors, such as mosquitoes, ticks, and fleas, to name a few. The burden o
  • Pirtobrutinib Approved as First-Line Treatment for CLL And SLL With No 17p Deletion

    Pirtobrutinib Approved as First-Line Treatment for CLL And SLL With No 17p Deletion
    Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHA new treatment option, pirtobrutinib (Jaypirca, Lilly), was approved for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no 17p deletion.Patients in the phase 3 BRUIN CLL-313 randomized controlled trial (NCT05023980) were randomized to receive either pirtobrutinib or bendamustine plus rituximab. A total of 282 patients with previously untrea
  • Milla Pharmaceuticals’ 8.4% Sodium Bicarbonate Injection, USP Now Available

    Milla Pharmaceuticals’ 8.4% Sodium Bicarbonate Injection, USP Now Available
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Credit: Milla PharmaceuticalsMilla Pharmaceuticals Inc., the U.S. subsidiary of A.forall, announced that its FDA-approved 8.4% Sodium Bicarbonate Inj

Follow @newsl_pharmacy on Twitter!